[{"orgOrder":0,"company":"Cellino","sponsor":"Karis Bio","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Partnership","leadProduct":"iPSC-EC","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cellino","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellino \/ Karis Bio","highestDevelopmentStatusID":"6","companyTruncated":"Cellino \/ Karis Bio"}]

Find Clinical Drug Pipeline Developments & Deals by Cellino

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : The partnership aims to industrialize the world’s first clinical-stage autologous iPSC-derived cell therapy for peripheral artery disease (PAD) and coronary artery disease (CAD).

                          Product Name : iPSC-EC

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 15, 2025

                          Lead Product(s) : iPSC-EC

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Karis Bio

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank